Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC
A single-arm phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status of 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
Metastatic Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma
DRUG: Pembrolizumab
Disease control rate at 24 weeks assessed using iRECIST, Disease control rate (proportion of patients with CR, PR or SD) assessed using iRECIST, 24 weeks after registration
Disease control rate assessed using iRECIST, Disease control rate (proportion of patients with CR, PR or SD) assessed using iRECIST, 12 months after registration|Best Response Rate- measured using the change from baseline tumour size. Assessed using iRECIST., Best Response Rate, defined as proportion of patients who have a CR or PR as their best response, measured using the change from baseline tumour size, assessed using iRECIST, 6 months after registration|Clinical Benefit Rate -defined as patient's best response rate lasting at least 18 weeks, Clinical Benefit Rate, defined as proportion patients who have achieved CR, PR or SD as their best response lasting at least 18 weeks, From start of treatment to 30 months post start of treatment|Duration of Response- defined as the time from first documented evidence of CR or PR until disease progression or death., Duration of Response, defined as the time from first documented evidence of CR or PR until disease progression or death, From start of treatment to 30 months post start of treatment|Time to Progression -defined as time from registration to the first documented disease progression, Time to Progression, defined as time from registration to the first documented disease progression, From registration to 30 months post start of treatment|Progression Free Survival defined as the time from registration to the first documented disease progression or death due to any cause, whichever occurs first., Progression Free Survival, defined as the time from registration to the first documented disease progression or death due to any cause, whichever occurs first., From registration to 30 months post start of treatment|Overall Survival- defined as the time from registration to death due to any cause., Overall Survival, defined as the time from registration to death due to any cause., From registration to 30 months post start of treatment|Frequency and severity of adverse events- throughout the patient's treatment and until 6 months after completion of trial treatment., Frequency and severity of adverse events, From date of registration until 6 months after completion of trial treatment
A single-arm phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status of 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months